Platelet Aggregation

Increased platelet aggregation may be an important risk marker for the occurrence of cardiovascular disease, and different types of fatty acids can modify platelet aggregation in vitro. However, reports of research on this topic are confusing. All measurements have their limitations, and it is not known whether measurement in vitro of platelet aggregation reflects the reality of platelet reactivity in vivo.

Many methods are available to measure platelet aggregation in vitro. First, the blood sample is treated with an anticoagulant to avoid clotting of the blood in the test tube or in the aggregometer; many different anticoagulants are used, which all differ in their mechanism of action. Second, platelet aggregation can be measured in whole blood, in platelet-rich plasma, or (to remove the influence of the plasma constituents) in a washed platelet sample. Finally, the platelet aggregation reaction in the aggregometer can be initiated with many different compounds, such as collagen, ADP, arachidonic acid, and thrombin. Platelet aggregation can also be studied by measuring the stable metabolites of the proaggregatory thromboxane A2 (TxA2), thromboxane B2 (TxB2), the stable metabolite of the antiaggregatory prostaglandin (prostacyclin: PGl2), or 6-keto-PGF1a.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment